IOVANCE INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Continues Investigation on Behalf of Long-Term Iovance, Inc. Stockholders

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance Biotherapeutics, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during the specified class period from May 9, 2024, to May 8, 2025 [1][6]. Company Summary - Iovance Biotherapeutics, Inc. is facing scrutiny following a class action complaint filed on May 15, 2025, which claims that the company provided misleading statements regarding its growth potential and was not adequately prepared to meet demand for its treatments [1][6]. - The company announced its financial results for Q2 of fiscal 2024 on July 25, 2024, and subsequently lowered its revenue guidance for the full fiscal year 2024 due to several factors, including maintenance issues and lower-than-expected sales [6]. - Following the announcement of reduced guidance, Iovance's stock price experienced a significant decline, dropping from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025, marking a decrease of approximately 44.8% in just one day [6].